Results of a 2-Arm, Phase 2 Clinical Trial Using Post-Transplantation Cyclophosphamide for the Prevention of Graft-Versus-Host Disease in Haploidentical Donor and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation

BACKGROUND: High-dose, post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD) has improved outcomes in haploidentical (HAPLO) stem cell transplantation (SCT). However, it remains unclear whether this strategy is effective in SCT from 1-antigen human leukocyte antige...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Gaballa, Sameh, Ge, Isabell, Fakih, Riad El, Brammer, Jonathan E., Kongtim, Piyanuch, Tomuleasa, Ciprian, Wang, Sa A., Lee, Dean, Petropoulos, Demetrios, Cao, Kai, Rondon, Gabriela, Chen, Julianne, Hammerstrom, Aimee, Lombardi, Lindsey, Alatrash, Gheath, Korbling, Martin, Oran, Betul, Kebriaei, Partow, Ahmed, Sairah, Shah, Nina, Rezvani, Katayoun, Marin, David, Bashir, Qaiser, Alousi, Amin, Nieto, Yago, Qazilbash, Muzaffar, Hosing, Chitra, Popat, Uday, Shpall, Elizabeth J., Khouri, Issa, Champlin, Richard E., Ciurea, Stefan O.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5459484/
https://ncbi.nlm.nih.gov/pubmed/27404668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30180
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items